drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified T cells)
drug_description
Allogeneic donor-derived T cells genetically modified via lentiviral transduction to express a CD33-specific CAR with a CD8 hinge, 4-1BB costimulatory, and CD3ζ signaling domains, including a truncated EGFR (EGFRt) safety tag for potential ablation; designed to target CD33+ AML cells.
nci_thesaurus_concept_id
C201495
nci_thesaurus_preferred_term
Anti-CD33 CAR T Cells Preparation
nci_thesaurus_definition
A preparation of T-lymphocytes that express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD33.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells are lentivirally engineered to express a CD33-specific CAR with 4-1BB costimulation and CD3ζ signaling. Upon binding CD33 on AML cells, the CAR activates T-cell cytotoxicity and proliferation, leading to targeted lysis of CD33+ cells; a truncated EGFR tag enables cetuximab-mediated ablation as a safety switch.
drug_name
Anti-CD33 CAR T cells
nct_id_drug_ref
NCT05672147